Danaher Q3 Preview: Market Share Gains In Molecular Testing

I reiterated my ‘Strong Buy’ rating for Danaher (NYSE: DHR ) in my previous article published in April 2024, pointing out Danaher’s worst time has already passed. The company’s Q2 result on July 23 demonstrated furtherMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth potential, a solid management team, a ...